Note: this article provided by ONU Healthwise Pharmacy.
The US Food and Drug Administration (FDA) has approved another biosimilar to a drug that treats breast, stomach and esophageal cancer.
This biosimilar is called Kanjinti (trastuzumab-anns). The FDA approved it because it appeared to have no meaningful differences from Herceptin (trastuzumab), which has already been approved.
If a drug is a biosimilar to another drug, that means it is nearly identical to the other drug (called the reference product). According to the FDA's recent approval, Kanjinti is a biosimilar to Herceptin.
By Chris Steffan, RN, ADON Birchaven Village
Dementia is a general term used to describe various symptoms of cognitive decline including impairment in memory, communication and thinking, which is caused by damage to cells in the brain. The symptoms do not appear suddenly but build over time and become more noticeable. Damage can occur for many reasons including increased proteins inside and outside of brain cells, lack of oxygen to the brain, stroke, genetics, medication side effects, depression, alcohol use, and thyroid and vitamin deficiencies.
Here's a view of Willeke Avenue earlier this week. Hohenbrink Construction of Findlay handling the Reconstruction Phase II project. In case you are interested in seeing what's happening below the surface check out additional photos in this series.
By Brian Paris
ONU Communications and Marketing
Ohio Northern University football players will play with more confidence this fall knowing that the finest football helmet on the market is protecting them.
Thanks to a generous gift to the Polar Bear Club from the Walt and Teri Bettinger Foundation, every player on the Polar Bear roster will have the opportunity to wear a new state-of-the-art VICIS Zero1 football helmet.
It is the top-rated helmet by the National Football League Players Association for three years running.
